CREDO: A structural interactomics database for drug discovery

Database

Volumn 2013, Issue , 2013, Pages

  Schreyer, Adrian M ^a   Blundell, Tom L ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; IMATINIB; LIGAND; NRH - QUINONE OXIDOREDUCTASE2; NRH QUINONE OXIDOREDUCTASE2; PIPERAZINE DERIVATIVE; PROTEIN; PYRIMIDINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ALGORITHM; ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CLUSTER ANALYSIS; COMPUTER INTERFACE; DRUG DEVELOPMENT; HUMAN; INTERNET; PROTEIN DATABASE; PROTEIN SECONDARY STRUCTURE;

ALGORITHMS; BENZAMIDES; BINDING SITES; CLUSTER ANALYSIS; DATABASES, PROTEIN; DRUG DISCOVERY; HUMANS; INTERNET; LIGANDS; MODELS, MOLECULAR; PIPERAZINES; PROTEIN STRUCTURE, SECONDARY; PROTEINS; PYRIMIDINES; QUINONE REDUCTASES; USER-COMPUTER INTERFACE;

EID: 84885906091     PISSN: 17580463     EISSN: None     Source Type: Journal    
DOI: 10.1093/database/bat049     Document Type: Article

References (44)

1. Ondetti,M.A. and Cushman,D.W. (1982) Enzymes of the reninangiotensin system and their inhibitors. Ann. Rev. Biochem., 51, 283-308.
2. Szelke,M., Leckie,B., Hallett,A. et al. (1982) Potent new inhibitors of human renin. Nature, 299, 555-557.
3. Blundell,T., Sibanda,B.L. and Pearl,L. (1983) Three-dimensional structure, specificity and catalytic mechanism of renin. Nature, 304, 273-275.
4. Miller,M., Schneider,J., Sathyanarayana,B.K. et al. (1989) Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science, 246, 1149-1152.
5. Lapatto,R., Blundell,T., Hemmings,A. et al. (1989) X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes. Nature, 342, 299-302.
6. Wlodawer,A. (2002) Rational approach to AIDS drug design through structural biology. Ann. Rev. Med., 53, 595-614.
7. Schreyer,A. and Blundell,T. (2009) CREDO: A Protein-Ligand Interaction Database for Drug Discovery. Chem. Biol. Drug Des., 73, 157-167.
8. Weisel,M., Bitter,H.M., Diederich,F. et al. (2012) PROLIX: rapid mining of protein-ligand interactions in large crystal structure databases. J. Chem. Inf. Model., 52, 1450-1461.
9. Roche,O., Kiyama,R. and Brooks,C. (2001) Ligand-protein database: linking protein-ligand complex structures to binding data. J. Med. Chem., 44, 3592-3598.
10. Berman,H.M., Westbrook,J., Feng,Z. et al. (2000) The protein data bank. Nucleic Acids Res., 28, 235-242.
11. Rees,D., Congreve,M., Murray,C. et al. (2004) Fragment-based lead discovery. Nat. Rev. Drug. Discov., 3, 660-672.
12. Greer,J. and Hajduk,P. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov., 6, 211-219.
13. Blundell,T.L., Jhoti,H. and Abell,C. (2002) High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov., 1, 45-54.
14. Higueruelo,A.P., Schreyer,A. et al. (2009) Atomic interactions and profile of small molecules disrupting protei1n-protein interfaces: the TIMBAL database. Chem. Biol. Drug Design, 74, 457-467.
15. Winter,A., Higueruelo,A.P., Marsh,M. et al. (2012) Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. Q. Rev. Biophys., 45, 1-44.
16. Bickerton,G.R., Higueruelo,A.P. and Blundell,T.L. (2011) Comprehensive, atomic-level characterization of structurally characterized protein-protein interactions: the PICCOLO database. BMC bioinformatics, 12, 313.
17. Lee,S. and Blundell,T.L. (2009) BIPA: a database for protein-nucleic acid interaction in 3D structures. Bioinformatics, 25, 1559-60.
18. Brewerton,S. (2008) The use of protein-ligand interaction fingerprints in docking. Curr. Opin. in Drug Discovery & development, 11, 356-364.
19. Deng,Z., Chuaqui,C. and Singh,J. (2004) Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. J. Med. Chem., 47, 337-344.
20. Chuaqui,C., Deng,Z. and Singh,J Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. J. Med. Chem., 47, 337-344.
21. Voth,A., Hays,F. and Ho,P. (2007) Directing macromolecular conformation through halogen bonds. Proc. Natl Acad. Sci. USA, 104, 6188-6193.
22. Auffinger,P., Hays,F.A., Westhof,E. and Ho,P.S. (2004) Halogen bonds in biological molecules. Proc. Natl Acad. Sci. USA, 101, 16789-16794.
23. Bissantz,C., Kuhn,B. and Stahl,M. (2010) A medicinal chemist's guide to molecular interactions. Journal of medicinal chemistry, 53, 5061-84.
24. Allen,F.H., Baalham,C.A., Lommerse,J.P.M. and Raithby,P.R. (1998) Carbonyl-Carbonyl Interactions can be Competitive with Hydrogen Bonds. Acta Crystallogr. Sec. B, 54, 320-329.
25. Winger,J., Hantschel,O., Furga,G.S. et al. (2009) The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct. Biol., 9, 7.
26. Chakrabarti,P. and Bhattacharyya,R. (2007) Geometry of non-bonded interactions involving planar groups in proteins. Progr. Biophys. Mol. Biol., 95, 83-137.
27. Graves,B., Thompson,T., Xia,M. et al. (2012) Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc. Natl Acad. Sci. USA, 109, 11788-11793.
28. Warren,G.L., Do,T.D., Kelley,B.P. et al. (2012) Essential considerations for using protein-ligand structures in drug discovery. Drug Discov. Today, 17, 1270-1281.
29. Cruickshank,D.W.J. (1999) Remarks about protein structure precision. Acta Crystallogr. Sec D Biol Crystallogr, 55, 583-601.
30. Blow,D.M. (2002) Rearrangement of cruickshank's formulae for the diffraction-component precision index. Acta Crystallogr. Sec D Biol Crystallogr., 58, 792-797.
31. Goto,J., Kataoka,R., Muta,H. et al. (2008) ASEDock-docking based on alpha spheres and excluded volumes. J. Chem. Inf. Modeling, 48, 583-590.
32. Gaulton,A., Bellis,L.J., Bento,A.P. et al. (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res., 40, D1100-D1107.
33. Schreyer,A.M. and Blundell,T. (2012) USRCAT: real-time ultrafast shape recognition with pharmacophoric constraints. J. Cheminform., 4, 27.
34. Nicholls,A., McGaughey,G.B., Sheridan,R.P. et al. (2010) Molecular shape and medicinal chemistry: a perspective. J. Med. Chem., 53, 3862-3886.
35. Smits,S.A. and Ouverney,C.C. (2010) jsPhyloSVG: a javascript library for visualizing interactive and vector-based phylogenetic trees on the web. PLoS One, 5, e12267.
36. Lewell,X.Q., Judd,D.B., Watson,S.P. et al. (1998) RECAPRetrosynthetic Combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Model., 38, 511-522.
37. Landrum,G. RDKit: Open-source cheminformatics, http://www.rdkit.org.
38. Bickerton,G.R., Paolini,G. V, Besnard,J. et al. (2012) Quantifying the chemical beauty of drugs. Nat. Chem., 4, 90-98.
39. Ballester,P.J. and Richards,W.G Ultrafast shape recognition to search compound databases for similar molecular shapes. J. Comput. Chem., 28, 1711-1723.
40. Ballester,P.J., Westwood,I., Laurieri,N. et al. (2010) Prospective virtual screening with Ultrafast Shape Recognition: the identification of novel inhibitors of arylamine N-acetyltransferases. J. R. Soc. Interface, 7, 335-42.
41. Weill,N. and Rognan,D. (2010) Alignment-free ultra-high-throughput comparison of druggable protein-ligand binding sites. J. Chem. Inform. Model., 50, 123-135.
42. Tanramluk,D., Schreyer,A., Pitt,W.R. et al. (2009) On the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporine. Chem. Biol. Drug Des., 74, 16-24.
43. Hubbard,T.J., Aken,B.L., Beal,K. et al. (2007) Ensembl 2007. Nucleic Acids Res., 35, 610-617.
44. Qiu,X., Mistry,A., Ammirati,M.J. et al. (2007) Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat. Struct. Mol. Biol., 14, 106-113.